• The Advisory Committee on Immunization Practices (ACIP), overhauled by Robert F. Kennedy Jr., is poised to vote on delaying universal hepatitis B vaccination from birth to age 4.
  • The policy shift could lead to insurance companies dropping coverage for the early dose and may trigger a resurgence of the preventable disease, according to public health experts.
  • The move represents a significant break from decades of medical consensus and has drawn sharp criticism from patient advocates and infectious disease specialists.

In a move that would upend three decades of public health policy, the Centers for Disease Control and Prevention’s vaccine advisory panel is expected to recommend delaying universal hepatitis B vaccination for children until they are four years old. The new Advisory Committee on Immunization Practices (ACIP), which was entirely replaced by Kennedy in June 2024 with vaccine-skeptical figures, has scheduled a vote on the measure for September 18–19, 2025.

The policy would mark a stark reversal from the current standard, which calls for all newborns to receive the first dose within 24 hours of birth. That longstanding recommendation is widely credited by infectious disease experts for achieving a 99% reduction in pediatric hepatitis B infections in the U.S., effectively preventing cases of fatal liver disease and cancer that can develop from early childhood infection.

The proposed change would make an exception for infants born to mothers who are known to test positive for the virus. However, public health officials and patient advocates warn that this targeted approach is fraught with risk. “It’s frustrating and incomprehensible,” said Wendy Lo, a patient advocate quoted in background materials, who emphasized the life-altering consequences of chronic hepatitis B acquired in infancy. A significant concern is that maternal infections often go undiagnosed, leaving newborns unprotected under the new policy.

The economic and logistical ramifications are immediate. If adopted and approved by the CDC Director, the federal Vaccines for Children program would no longer be required to cover the birth dose. This would likely cause private insurance companies to cease coverage for hepatitis B vaccines administered before age four, pushing the cost onto families and potentially reducing overall vaccine demand, impacting manufacturers and healthcare providers.

The ACIP’s deliberations are occurring under a new structure that breaks from tradition. For the first time, major medical groups like the American Academy of Pediatrics and the American Medical Association have been barred from participating in the committee’s workgroups, signaling a definitive shift away from established medical consensus in federal vaccine policy making.

This potential rollback of the hepatitis B vaccine is seen by many analysts as a precedent-setting action. The same reconstituted panel is simultaneously reviewing the schedule for other routine childhood immunizations, including the MMRV and COVID-19 vaccines, suggesting a broader agenda to limit universal vaccine recommendations. The final decision, expected next fall, will be closely watched as a bellwether for the future of U.S. immunization policy.